Bulletin
Investor Alert

Nov. 9, 2021, 10:13 a.m. EST

Shortages of Covid-19 Tests Creates Accelerated Demand for New Diagnostic Technology

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Abbott Laboratories (ABT)
  • X
    Becton Dickinson & Co. (BDX)
  • X
    Quidel Corp. (QDEL)

or Cancel Already have a watchlist? Log In

"While COVID testing has been strongly contributing to growth, we expect our base direct-to-consumer testing revenue to more than double this year," said Quest CEO Stephen Rusckowsk.

Quest recently committed to help K-12 schools in Texas, through an agreement with the Texas Department of State Health Services (DSHS) to provide COVID-19 Kindergarten through Senior (K-12) school testing services to support safer classroom learning throughout the state of Texas.

"Testing is critical to containing COVID-19's spread and creating safer environments for all of us,” said Chad Richards, Vice President and General Manager, Southwest Region, Quest Diagnostics. “We applaud the state of Texas for recognizing the value of testing for children, faculty and staff, and look forward to bringing our high quality and convenient testing capabilities to participating schools in the program."

Article Source: https://biotech-insider.com/the-small-biotech-company-that-all-the-majors-aspire-to-be/

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Biotech Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for BioVaxys Technology Corp. advertising and digital media from the company directly. There may be 3rd parties who may have shares of BioVaxys Technology Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of BioVaxys Technology Corp. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of BioVaxys Technology Corp. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

COMTEX_396581060/2559/2021-11-09T10:12:42

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.